185,732 Shares in Kenvue Inc. $KVUE Purchased by Ieq Capital LLC

Ieq Capital LLC acquired a new position in shares of Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 185,732 shares of the company’s stock, valued at approximately $3,549,000.

A number of other institutional investors have also recently bought and sold shares of the stock. CoreCap Advisors LLC raised its stake in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after purchasing an additional 591 shares during the period. Montag A & Associates Inc. increased its holdings in shares of Kenvue by 6.3% during the 1st quarter. Montag A & Associates Inc. now owns 10,156 shares of the company’s stock worth $175,000 after buying an additional 600 shares during the last quarter. Cornerstone Wealth Group LLC increased its holdings in shares of Kenvue by 5.9% during the 1st quarter. Cornerstone Wealth Group LLC now owns 10,810 shares of the company’s stock worth $187,000 after buying an additional 606 shares during the last quarter. Physician Wealth Advisors Inc. raised its position in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares during the period. Finally, Mill Creek Capital Advisors LLC boosted its holdings in Kenvue by 0.6% in the fourth quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company’s stock valued at $2,143,000 after acquiring an additional 701 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $19.41 on Tuesday. The business’s 50-day simple moving average is $19.08 and its 200 day simple moving average is $18.21. The company has a market cap of $37.27 billion, a P/E ratio of 22.30, a PEG ratio of 1.36 and a beta of 0.47. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. Kenvue Inc. has a one year low of $14.02 and a one year high of $21.63.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The company had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.97 billion. During the same quarter in the prior year, the company earned $0.29 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be paid a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 4.3%. This is a boost from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, August 12th. Kenvue’s payout ratio is currently 96.55%.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of research reports. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Barclays lifted their price target on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Zacks Research lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, UBS Group cut their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average target price of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.